Evrys Bio

Evrys Bio is an early-stage biotech pioneering a novel antiviral approach through allosteric modulation of the host protein SIRT2. This strategy aims to create broad-spectrum therapies that are less susceptible to viral resistance by targeting the host's metabolic reprogramming during infection. Led by a seasoned team with strong academic and industry backing, the company is advancing its lead candidate, EV-100, while leveraging significant non-dilutive funding. Its platform holds potential not only for infectious diseases but also for conditions like oncology and neurodegeneration.

Platform of allosteric, small-molecule modulators of the host protein SIRT2, designed to disrupt viral-induced metabolic reprogramming for broad-spectrum antiviral activity with a high barrier to resistance.

The competitive landscape includes direct-acting antivirals for specific viruses and other companies exploring host-targeted approaches. Evrys Bio's differentiation lies in its specific focus on allosteric SIRT2 modulation for metabolic reprogramming, a novel angle within the host-targeting field.